Molecular Partners publishes MP0317 clinical data in Nature Cancer

Molecular Partners (MOLN) announced the publication of Phase 1 clinical data in Nature Cancer demonstrating the potential of the tumor-localized CD40 agonist, MP0317, to modulate the tumor microenvironment. MP0317 is designed to activate immune cells specifically within the TME by anchoring to fibroblast activation protein, which is expressed in high amounts in the stroma of various solid tumors. This tumor-localized approach has the potential to deliver greater efficacy with fewer side effects compared to systemic CD40-targeting therapies. The peer-reviewed paper published by Steehgs et al., entitled “Tumor-localized CD40 agonism with MP0317, a FAPxCD40 DARPin, reprograms the tumor microenvironment – results of a Phase 1 monotherapy study”, reports the positive results from the completed Phase 1 dose escalation study of MP0317. The comprehensive biomarker data confirm proof-of-mechanism for MP0317, including tumor-localized activation of the CD40 pathway and evidence of TME remodeling in patients with advanced solid tumors. MP0317 displayed a favorable safety profile up to the highest tested dose and serum pharmacokinetics confirmed suitability for dosing either weekly or every three weeks. Of the 46 patients in the study, one patient achieved an unconfirmed partial response and 14 patients stable disease in this heterogeneous population with advanced diseases. Data were presented at the 2024 Annual Meetings of the American Society of Clinical Oncology and of the Society for Immunotherapy of Cancer.